AMD

Answers to the Three Big Questions of Long-Term Treatment of Wet AMD

Anti-VEGF agents have forced us to choose an agent and regimen, and learn when enough is enough.

Retina Report from ARVO 2016

A closer look at five abstracts on VMT, DME, AMD, OCT and gene therapy.

TAE for Wet AMD: Practical Tips from the Pros

A conversation on the nuances of implementing treat and extend.

Subclinical MNV: Do We Watch or Treat?

Now that we have OCT-A, we can no longer ignore macular neovascularization in non-exudative AMD.

Big Data and AMD Progression

Gathering and analyzing imaging biomarkers from SD-OCT along with other inputs can aid in tracking patients.

Dry AMD Progression in Wet AMD

What we know and don’t know about geographic atrophy.

A Quick Look at CHROMA, SPECTRI

Lead investigator provides details on parallel trials of lampalizumab.

Can Anti-VEGF Cause GA in Wet AMD?

A host of trials are trying to answer this question. Here’s what they’ve found so far.